These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22511225)

  • 1. Proteasome inhibitors mechanism; source for design of newer therapeutic agents.
    Harer SL; Bhatia MS; Bhatia NM
    J Antibiot (Tokyo); 2012 Jun; 65(6):279-88. PubMed ID: 22511225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors: complex tools for a complex enzyme.
    Bogyo M; Wang EW
    Curr Top Microbiol Immunol; 2002; 268():185-208. PubMed ID: 12083006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for selective small molecule inhibitors of the proteasome using activity-based probes.
    Bogyo M
    Methods Enzymol; 2005; 399():609-22. PubMed ID: 16338384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitors of proteasome activity.
    Gaczynska M; Osmulski PA
    Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors: Dozens of molecules and still counting.
    de Bettignies G; Coux O
    Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors.
    Bayot A; Basse N; Lee I; Gareil M; Pirotte B; Bulteau AL; Friguet B; Reboud-Ravaux M
    Biochimie; 2008 Feb; 90(2):260-9. PubMed ID: 18021745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors for cancer therapy.
    Iqbal M; Messina McLaughlin PA; Dunn D; Mallya S; Husten J; Ator MA; Chatterjee S
    Bioorg Med Chem; 2012 Apr; 20(7):2362-8. PubMed ID: 22377673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent and non-covalent reversible proteasome inhibition.
    Beck P; Dubiella C; Groll M
    Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates.
    Buckley DL; Corson TW; Aberle N; Crews CM
    J Am Chem Soc; 2011 Feb; 133(4):698-700. PubMed ID: 21186803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
    Tsukamoto S; Yokosawa H
    Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteasome and proteolysis].
    Papapostolou D; Reboud-Ravaux M
    J Soc Biol; 2004; 198(3):263-78. PubMed ID: 15662944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Dick LR; Fleming PE
    Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitors in cancer therapy: lessons from the first decade.
    Orlowski RZ; Kuhn DJ
    Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.
    Groll M; Gallastegui N; Maréchal X; Le Ravalec V; Basse N; Richy N; Genin E; Huber R; Moroder L; Vidal J; Reboud-Ravaux M
    ChemMedChem; 2010 Oct; 5(10):1701-5. PubMed ID: 20715286
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.
    Baldisserotto A; Franceschini C; Scalambra F; Trapella C; Marastoni M; Sforza F; Gavioli R; Tomatis R
    J Pept Sci; 2010 Nov; 16(11):659-63. PubMed ID: 20814885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.